Drug Trial Radar · NCT07242352
Marker - Adjusted Therapy Comparing Adjuvant Elacestrant With Standard Endocrine Treatment in Genomically and/or Clinically High-risk ER+/HER2- eBC
Last checked: Nov 19, 2026Latest source record: Aug 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,520
Planned (sponsor's estimate)
Start
Apr 29, 2026
Primary completion
Sep 30, 2033
Study completion Sep 30, 2033
Sponsor
- Lead sponsor
- Women's Cancer Study Group GmbHAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Berlin-Chemie Menarini
- First posted
- Nov 21, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In this clinical trial, the Sponsor plans to investigate whether patients with HR+/HER2- eBC identified during routine clinical assessments and treatments as having intermediate to high-risk (based on Oncotype DX® or similar tests and on response assessment to 2-6 weeks of preoperative ET) achieve a survival benefit from an initial 5-years use of elacestrant (with or without a CDK 4/6 inhibitor) followed by SoC ET for further 0-2.5 years in comparison to at least 5 up to 7.5 years SoC ET therapy (+/- CDK4/6 inhibitor). Based on several studies in the metastatic setting, it is reasonable to assume that the adjuvant use of elacestrant with or without CDK 4/6 inhibitors will prevent or delay the activation of mechanisms conferring resistance to ET (e.g., ESR1 mutations).
Conditions
- Breast Cancer
- HR+/HER2- Breast Cancer
Interventions
ElacestrantDrug
Elacestrant, a tetrahydronaphthalene compound, is a potent, selective, and orally active oestrogen receptor-α (ERα) antagonist and degrader.
Standard-of-care endocrine treatmentDrug
SoC ET comprises all endocrine treatments authorized for the condition under review. The choice is made upon investigator´s discretion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- 5-year invasive disease-free survival (iDFS)Time frame: iDFS 5 years
Locations
33 sites in 1 country. Site status is shown where the registry gives one.
Staedtisches Klinikum Lueneburg gGmbH Brustkrebszentrum Lueneburg
Lüneburg, Germany · Recruiting
Universitaetsklinikum Mannheim GmbH Frauenklinik
Mannheim, Baden-Wurttemberg, Germany · Recruiting
Universitaetsklinikum Tuebingen AöR Frauenklinik
Tübingen, Baden-Wurttemberg, Germany · Recruiting
Klinikum Esslingen GmbH Klinik für Frauenheilkunde und Geburtshilfe
Esslingen am Neckar, Baden-Wüttemberg, Germany · Recruiting
Praxis Fuer Interdisziplinaere Onkologie And Haematologie GbR
Freiburg im Breisgau, Baden-Wüttemberg, Germany · Recruiting
Klinikum St Marien Amberg Klinik für Frauenheilkunde und Geburtshilfe
Amberg, Bavaria, Germany · Recruiting
Haematologie-Onkologie im Zentrum MVZ GmbH
Augsburg, Bavaria, Germany · Not yet recruiting
Klinikum der Universitaet Muenchen AöR Frauenheilkunde und Geburtshilfe
München, Bavaria, Germany · Not yet recruiting
Rotkreuzklinikum Muenchen gGmbH Interdisziplinäres Brustzentrum
München, Bavaria, Germany · Recruiting
Haematologisch Onkologische Schwerpunktpraxis
Würzburg, Bavaria, Germany · Recruiting
Medical University Of Lausitz Carl Thiem Frauenklinik
Cottbus, Brandenburg, Germany · Recruiting
Mammazentrum Hamburg MVZ GbR
Hamburg, Free and Hanseatic City of Hamburg, Germany · Not yet recruiting
Hämatologische Onkologische Praxis im Medicum
Bremen, Free Hanseatic City of Bremen, Germany · Recruiting
Gesundheitszentrum Wetterau gGmbH Gynäkologische Ambulanz
Bad Nauheim, Hesse, Germany · Recruiting
Centrum für Hämatologie und Onkologie Bethanien
Frankfurt am Main, Hesse, Germany · Recruiting
Elisabeth Krankenhaus GmbH Brustzentrum
Kassel, Hesse, Germany · Recruiting
Medizinische Hochschule Hannover Klinik für Frauenheilkunde und Geburtshilfe Brustzentrum
Hanover, Lower Saxony, Germany · Recruiting
Gemeinschaftspraxis Frauenärzte am Bahnhofsplatz
Hildesheim, Niedersachen, Germany · Recruiting
Klinik Dr. Hancken GmbH
Stade, Niedersachen, Germany · Recruiting
Johanniter GmbH Onkologisches Zentrum
Bonn, North Rhine-Westphalia, Germany · Recruiting
Marienhospital Bottrop gGmbH Klinik für Gynäkologie und Geburtshilfe
Bottrop, North Rhine-Westphalia, Germany · Recruiting
Klinikum Dortmund gGmbH Frauenklinik Dortmund
Dortmund, North Rhine-Westphalia, Germany · Recruiting
Universitaetsklinikum Duesseldorf AöR Klinik für Frauenheilkunde und Geburtshilfe
Düsseldorf, North Rhine-Westphalia, Germany · Recruiting
St.-Antonius-Hospital gGmbH Klinik für Hämatologie und Onkologie
Eschweiler, North Rhine-Westphalia, Germany · Recruiting
St. Barbara-Klinik Hamm GmbH Brustzentrum
Hamm, North Rhine-Westphalia, Germany · Recruiting
Brustzentrum Niederrhein, Johanniter Bethesda Krankenhaus
Mönchengladbach, North Rhine-Westphalia, Germany · Recruiting
Stiftung Mathias-Spital Rheine Brustzentrum
Rheine, North Rhine-Westphalia, Germany · Recruiting
MKS St. Paulus GmbH Märkisches Brustzentrum
Schwerte, North Rhine-Westphalia, Germany · Recruiting
Praxisnetz Hämatologie / internistische Onkologie
Troisdorf, North Rhine-Westphalia, Germany · Recruiting
Marien-Hospital Witten Brustzentrum
Witten, North Rhine-Westphalia, Germany · Recruiting
Helios Universitaetsklinikum Wuppertal Landesfrauenklinik - Brustzentrum
Wuppertal, North Rhine-Westphalia, Germany · Not yet recruiting
Klinikum Mutterhaus der Borromaeerinnen gGmbH
Trier, Rhineland-Palatinate, Germany · Recruiting
HELIOS Klinikum Berlin-Buch GmbH Klinik für Gynäkologie und Geburtshilfe
Berlin, State of Berlin, Germany · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.